Abbott Laboratories (ABT) SEC filings

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/3049% above fair value

$108.52+1.27 (+1.18%)

Close on Nov 13, 2026Market cap $187.78BP/E 40.2Yield 2.21%

SEC filings

40 of Abbott Laboratories's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	8-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	8-K	Aug 20, 2026	Aug 20, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Jul 28, 2026	SEC EDGAR
Current report	8-K	Jul 16, 2026	Jul 16, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	Apr 29, 2026	SEC EDGAR
Current report	8-K	Apr 24, 2026	Apr 27, 2026	SEC EDGAR
Current report	8-K	Apr 10, 2026	Apr 17, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 16, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 24, 2026	Mar 13, 2026	SEC EDGAR
Current report	8-K	Mar 9, 2026	Mar 9, 2026	SEC EDGAR
Current report	8-K	Feb 23, 2026	Feb 26, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 20, 2026	SEC EDGAR
Current report	8-K	Feb 20, 2026	Feb 20, 2026	SEC EDGAR
Current report	8-K	Jan 22, 2026	Jan 22, 2026	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 12, 2025	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 21, 2025	SEC EDGAR
Current report	8-K	Nov 19, 2025	Nov 20, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Oct 29, 2025	SEC EDGAR
Current report	8-K	Oct 15, 2025	Oct 15, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jul 17, 2025	Jul 17, 2025	SEC EDGAR
Current report	8-K	Apr 25, 2025	May 1, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	Apr 30, 2025	SEC EDGAR
Current report	8-K	Apr 25, 2025	Apr 28, 2025	SEC EDGAR
Current report	8-K	Apr 16, 2025	Apr 16, 2025	SEC EDGAR
Proxy statement	DEF 14A	Apr 25, 2025	Mar 14, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 21, 2025	SEC EDGAR
Current report	8-K	Jan 22, 2025	Jan 22, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 15, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Oct 31, 2024	SEC EDGAR
Current report	8-K	Oct 16, 2024	Oct 16, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Jul 31, 2024	SEC EDGAR
Current report	8-K	Jul 18, 2024	Jul 18, 2024	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2024	May 2, 2024	SEC EDGAR
Current report	8-K	Apr 26, 2024	May 1, 2024	SEC EDGAR
Current report	8-K	Apr 26, 2024	Apr 29, 2024	SEC EDGAR
Current report	8-K	Apr 17, 2024	Apr 17, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Abbott Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 1, 1998
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABT.

Compare: ABT vs ABBV · ABT vs LLY · ABT vs JNJ · ABT vs PFE · ABT vs VTRS

Revenue growth10.0% · median 7.8%

Gross margin56.9% · median 71.5%

Operating margin13.8% · median 13.1%

Net margin9.7% · median 13.0%

Company	Revenue	Growth
JNJ	$99.34B	+7.8%
LLY	$86.46B	+45.5%
ABBV	$64.39B	+10.4%
PFE	$63.63B	+1.3%
ABT	$48.23B	+10.0%
VTRS	$14.73B	+4.3%

Company

Next earnings (est.): Jan 21, 2027, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 115,000
Held by institutions: 79.8%
Auditor: Ernst & Young LLP
SEC CIK: 1800

Advertisement
300 × 250

See a number that looks wrong?